News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|January 23, 2025

Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

Panelists discuss how they envision the future of industry-provided and other patient support services in hematology-oncology, highlighting potential improvements and innovations that could be implemented in the near future.

Episodes in this series

EP. 1 Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP. 1 Challenges at Diagnosis: Navigating the Emotional and Physical Realities of DLBCL and FL

EP. 2 Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP. 2 Empowering Patients: Strategies for Emotional Resilience and Support in Lymphoma Care

EP. 3 Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

EP. 3 Tailored Support: The Role of Industry-Provided Services in Lymphoma Care

EP. 4 Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

EP. 4 Seamless Transitions: Supporting Patients Through Treatment, Monitoring, and Maintenance

EP. 5 Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

EP. 5 Innovations and Impact: The Future of Patient Support Services in Hematology-Oncology

Video content above is prompted by the following:

What do you think is the future of industry-provided and other patient support services in hematology-oncology, and what improvements or innovations would you like to see implemented in the near future?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

Additional Emerging HER2-Targeted Therapies in NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Joshua K. Sabari, MD,Jingxiao Jin, MD,Fred Hirsch, MD, PhD

February 4th 2026

Addressing Care Coordination and Financial Toxicity in HER2+ Breast Cancer

ByTiffany Traina, MD, FASCO,Mark Pegram, MD,Sherry Shen, MD,Jules Cohen, MD,Rochelle Horadam, RPh, BCOP

February 4th 2026

5 experts are featured in this series

Safety Considerations and Practical Strategies for Using Bispecific Antibodies in Multiple Myeloma

ByZahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA ,Brooke Adams, PharmD, BCOP,Thomas Martin, MD,Raymond Thertulien, MD, PhD,Laura Joiner, PharmD, BCOP

February 3rd 2026

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

AJMC Supplement

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

2.0 Credits / Pain Management

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text